地塞米松磷酸钠(Dexamethasone Sodium Phosphate) - 药物靶点：GR_在研适应症：脑水肿，新型冠状病毒感染，急性呼吸窘迫综合征_专利_临床

概要

基本信息

药物类型

小分子化药

别名

EryDex、AVM-0703、DM001

+ [20]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [10]

在研适应症

脑水肿新型冠状病毒感染急性呼吸窘迫综合征+ [31]

非在研适应症

过敏白内障干眼综合征+ [16]

原研机构

Merck & Co., Inc.

在研机构

Hameln pharma Gmbh.

Fuji Pharma Co., Ltd.山德士有限公司

+ [7]

非在研机构

Scilex Pharmaceuticals, Inc.

Aspen Global, Inc.

UCB, Inc.

+ [4]

权益机构

台湾微脂体股份有限公司

Bausch Health Cos., Inc.

Endo International Plc

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1959-08-26)

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C22H30FNaO8P

InChIKeyVIKBYTWZYXGHAT-WKSAPEMMSA-N

CAS号2392-39-4

关联

2,141

项与地塞米松磷酸钠相关的临床试验

NCT07096778

/ Not yet recruiting临床2期

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

开始日期2025-12-01

申办/合作机构

CellCentric Ltd.

NCT07084441

/ Not yet recruiting临床4期IIT

Comparison of Outcomes of Management of Bowel Obstruction

The Comparison of Outcomes of Management of Bowel Obstruction (COMBO) trial is a patient-level randomized trial of a short course of dexamethasone + supportive care vs supportive care alone for patients with adhesion-related small bowel obstruction (aSBO). The goal of the COMBO trial is to answer the question: Can Dexamethasone increases the proportion of patients with resolution of aSBO with non-operative management (without complication) based on an established minimal important clinical difference.

开始日期2025-12-01

申办/合作机构

University of Washington

[+1]

NCT07097493

/ Not yet recruiting临床4期IIT

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty

The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine, clonidine, epinephrine, buprenorphine, and dexamethasone. Pain scores will be collected at different intervals during study participation.

开始日期2025-12-01

申办/合作机构

Wake Forest School of Medicine

100 项与地塞米松磷酸钠相关的临床结果

登录后查看更多信息

100 项与地塞米松磷酸钠相关的转化医学

登录后查看更多信息

100 项与地塞米松磷酸钠相关的专利（医药）

登录后查看更多信息

2,190

项与地塞米松磷酸钠相关的文献（医药）

2025-12-31·mAbs

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

作者: Gesner, Thomas ; Logel, Claude ; Xie, Kathleen T. ; Cebe, Regis ; Wu, Nila C. ; Li, Xun ; Shi, Xingyi ; Velazquez, Roberto ; Simmons, Quincey ; Tschantz, William R. ; Barzaghi-Rinaudo, Patrizia ; Korn, Joshua ; Sagar, Vivek ; Hainzl, Dominik ; Malamas, Anthony ; Mercan, Samuele ; Green, Andrew ; McLaughlin, Margaret ; Huber, Thomas ; Mueller, Kathrin ; D’Alessio, Joseph A. ; Synan, Alyssa

P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC).In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17.Based on in vitro binding and inhibition of cell proliferation results, we selected a lead bispecific antibody to link to the cytotoxic payload monomethyl auristatin E (MMAE) to generate a pCAD x CDH17 bispecific MMAE ADC.In in vivo dual flank mouse models, we demonstrated antitumor activity of the bispecific ADC in tumors expressing both antigens but not in tumors expressing only pCAD or only CDH17.Overall, the preclin. data presented here support the proof-of-concept bispecific antibody discovery approach, demonstrating a rational design for screening antibodies by prioritizing cross-arm avid IgGs to target dual-pos. cells.

2025-08-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Zwitterionic printlets via vat photopolymerisation: A cutting-edge platform for controlled oral drug release systems

Article

作者: Deon, Monique ; de Oliveira, João Vítor Raupp ; Beck, Ruy Carlos Ruver ; Buchner, Silvio

Vat photopolymerisation 3D printing has attracted considerable interest as an innovative technology for producing personalised medicines. However, the limited availability of materials suitable for printing pharmaceutical forms remains a significant barrier to progress in the field. Zwitterionic materials have recently emerged as promising next-generation biomaterials, offering a viable alternative for 3D printing of novel biocompatible systems. In this study, we report for the first time the use of a drug-loaded zwitterionic photopolymerisable formulation to fabricate advanced drug delivery systems. LCD 3D printing was employed to produce zwitterionic hydrogel forms loaded with dexamethasone sodium phosphate, using a biocompatible riboflavin/triethanolamine-based photoinitiator system. Drug-loaded zwitterionic solid forms were subsequently obtained through dehydration of the hydrogel structures. Printlets - comprising both hydrogel and solid states with tailored dosages - were manufactured by adjusting the diameter of the 3D-designed cylinders. Drug release from printlets of varying sizes occurred in a controlled manner over a period of up to 10 h, with the solid forms exhibiting a slower dissolution rate. This research demonstrates the feasibility of using drug-loaded zwitterionic photopolymerisable formulations as potential materials for the fabrication of personalised drug delivery systems via vat photopolymerisation 3D printing.

2025-07-17·JOURNAL OF CLINICAL ONCOLOGY

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Article

作者: Ferdinandus, Justin ; Balabanov, Stefan ; Mey, Ulrich ; Hüttmann, Andreas ; Roncolato, Fernando ; Hertzberg, Mark ; Tharmaseelan, Hishan ; Ko, Yon-Dschun ; Hellmuth, Johannes C ; Wille, Kai ; Trenker, Corinna ; Eichenauer, Dennis A ; Staib, Peter ; Kerkhoff, Andrea ; Borchmann, Peter ; Kobe, Carsten ; Fosså, Alexander ; Dresel, Irmgard ; Keil, Felix ; Kreissl, Stefanie ; Kaul, Helen ; Armytage, Tasman ; Klapper, Wolfram ; Eich, Hans-Theodor ; Moosmann, Peter ; Schneider, Gundolf ; Baues, Christian ; Hitz, Felicitas ; Jablonski, Janina ; Bröckelmann, Paul J ; von Tresckow, Bastian ; Fuchs, Michael ; Hahn, Dennis ; Schwarz, Michaela ; Hertenstein, Bernd

PURPOSE:

Positron emission tomography (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) is highly effective in younger patients with advanced-stage classic Hodgkin lymphoma (AS-cHL). We report feasibility and efficacy of PET-guided BrECADD as first-line treatment in older patients with AS-cHL.

PATIENTS AND METHODS:

Patients with AS-cHL aged 61-75 years were enrolled in a phase II single-arm cohort of the HD21 trial (ClinicalTrials.gov identifier: NCT02661503). Patients with negative PET/computed tomography after 2×BrECADD (PET2) received a total of 4×BrECADD, while PET2-positive patients received 6×BrECADD. The primary end point was the centrally reviewed complete remission (CR) rate after the end of chemotherapy (EOC). Secondary end points included feasibility, adverse events, treatment-related morbidity (TRMB), progression-free survival (PFS), overall survival (OS), and health-related quality of life (HRQoL).

RESULTS:

Between June 2020 and April 2023, 85 patients were enrolled, of whom 83 with a median age of 67 years (range, 61-75) were analyzed in the intention-to-treat cohort. Most prevalent ≥grade 3 toxicities included leukopenia (n = 80 [96%]), thrombocytopenia (n = 71 [86%]), anemia (n = 57 [69%]), and febrile neutropenia (n = 46 [55%]). Forty-eight (60%) of 80 patients with centrally reviewed PET2 were scheduled for 4×BrECADD and 32 (40%) for 6×BrECADD. Of these, 71 patients (89%) received the target number of cycles. Sixty-eight patients (82%; 95% CI, 72 to 90) achieved CR at EOC. PFS and OS estimates at 2 years were 91.5% (95% CI, 85 to 98) and 90.8% (95% CI, 84 to 98), respectively. No death was attributed to study treatment. Initially, impaired HRQoL scores improved during follow up and on average reached population reference values.

CONCLUSION:

PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL.

350

项与地塞米松磷酸钠相关的新闻（医药）

2025-08-26

·EINPresswire

PAIN FLEX may be harmful due to hidden drug ingredients

[8-22-2025] The Food and Drug Administration is advising consumers not to purchase or use PAIN FLEX, a product promoted and sold for joint pain on various websites, including Amazon.com and possibly in some retail stores. FDA laboratory analysis confirmed that PAIN FLEX contains dexamethasone and methocarbamol not listed on the product label. Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. Additionally, the undeclared dexamethasone may cause serious side effects when combined with other medications. Consumers taking PAIN FLEX should immediately consult with their health care professional to safely discontinue use of this product. The risks of withdrawal from corticosteroids should be assessed by a health care professional. Only licensed health care professionals can evaluate patients for the risk or existence of adrenal suppression. Methocarbamol is a muscle relaxant that can cause sedation, dizziness and low blood pressure. Methocarbamol also can impair mental and physical abilities to perform certain tasks, such as driving a motor vehicle or operating machinery. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 08/26/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-08-22

·创诺医药集团

产品之光：地塞米松棕榈酸酯注射液

产品之光通用名地塞米松棕榈酸酯注射液规格 1ml:4mg 产品类别糖皮质激素类原研企业田边三菱制药适应症类风湿关节炎关于本品 ☑ “地塞米松棕榈酸酯”具有向炎症部位聚集的特性，因此药效更持久，其抗炎作用是地塞米松的2-5倍； ☑ 适合慢性风湿性关节炎、哮喘、全身感染和各种恶性淋巴瘤等需要长期控制炎症性疾病的管理。 ☑ 其给药方式灵活，成人患者静脉注射为2周给药一次，可静脉注射/关节腔注射。 ☑ 相较于地塞米松磷酸钠等速效制剂，地塞米松棕榈酸酯副作用相对较轻。 ☑ 本品在疼痛治疗领域（疼痛科、风湿免疫科、骨科、康复科），专家给与了充分的认可，在多项指南/专家共识中获重点推荐：《中国慢性创伤后疼痛诊疗指南》、《膝骨关节炎糖皮质激素注射应用专家共识》、《正中神经阻滞疗法中国疼痛学与麻醉学专家共识》、《臂丛神经阻滞疗法中国疼痛科专家共识（2024 版）》。地塞米松棕榈酸酯注射液2022年前销售收入年复合增长率超过100%，2022年至今市场规模稳定在2900万美元左右。成都安礼特医药科技有限公司目前已完成“地塞米松棕榈酸酯注射液”产品的BE试验，预计将于2025年8月在中国完成申报。公司拥有稳定的原料药供应渠道，可确保供应的安全性与可持续性；公司已建成完整的皮质激素脂肪乳生产线，可实现高质量规模化生产；公司还可提供CRO/CDMO服务，或进行二次制剂开发服务。欢迎各位医药同仁垂询合作！合作咨询：王先生 18851890058 公司简介成都安礼特医药科技有限公司位于四川省成都市天府国际生物城，隶属于中国医药工业百强企业——上海创诺医药集团。作为集团的核心成员，我们专注于非肿瘤药物领域，凭借原料药与制剂一体化的全面布局，实现从研发至产业化的完整链条，为集团及其战略伙伴提供全面支持，强化其市场竞争力，推动可持续发展。公司建设有超8000m2的研发实验室，拥有近百人的研发团队，包括：战略规划、研发、技术转移、注册申报、知识产权/科技项目申报等研发和产业化全链条专业部门，可全方位保障项目落地和价值实现。公司具备完整的原料制剂一体化开发经验，成立3年多，已完成近30个制剂项目的中试及转移，6个项目提交药物上市注册申报，1个项目过评；原料药板块启动仅半年，已完成2个项目研发交付。企业优势： ☑ 从研发到市场准入的链条全流程服务； ☑ 具有特色的原料制剂一体化技术平台； ☑ 完善的研发质量管理及项目管理体系。

2025-08-21

·EndPoints

Sarepta refinances its debt; FDA delays decisions on Eylea HD

Plus, news about Benchling, Invivyd, Immuneering, Scilex and Sana Biotechnology: 📉 Sarepta’s debt refinancing: The biotech, which went through a complicated exchange with the FDA this summer over the safety of its Duchenne gene therapy, will extend its debt from 2027 to 2030 to improve its finances. “By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction,” CEO Doug Ingram said in a statement. Last week, the company had to sell its stock position in Arrowhead Pharmaceuticals to be able to pay a milestone fee to Arrowhead, which has siRNA programs that could drive the future of Sarepta’s pipeline under a $10 billion biobuck pact . — Kyle LaHucik 🏭 As expected, Regeneron says FDA decisions on Eylea HD are delayed: The regulator pushed back two decisions on Eylea’s high-dose formulations to the fourth quarter. The original decision date was Aug. 19. Regeneron is seeking approval for a pre-filled syringe, treatment for macular edema following retinal vein occlusion, and a broader dosing schedule for all indications. It previously disclosed that it expected delays following an inspection of a third-party manufacturer site in Indiana, formerly owned by Catalent and now part of Novo Nordisk. Scholar Rock , another customer of the Indiana site, has said it doesn’t expect any PDUFA delays for its experimental spinal muscular atrophy drug called apitegromab. — Anna Brown 💻 Benchling’s two deals: The life sciences software startup “acquired the teams” of ReSync Bio and Sphinx Bio. The startups create “AI tools that power scientific workflows,” Benchling said. Earlier this year, Benchling laid off 10% of its staff. The San Francisco-based company partners with biopharmas like Merck and Moderna on AI research, bioanalytics and other functions. It raised a $100 million Series F in 2021. — Kyle LaHucik 💰 Invivyd’s $50M stock sale: The company, which has an authorized Covid-19 prevention drug called Pemgarda, is selling 21.3 million shares at 52 cents apiece. — Jaimy Lee 🏥 Immuneering gets $25M from PIPE: The company said it expects to share updated overall survival and progression-free survival data from its Phase 2a trial of atebimetinib in pancreatic cancer “in the coming weeks.” — Jaimy Lee 💵 Scilex raises $20M for Phase 3 trial: Semnur Pharmaceuticals, Scilex’s parent company, and Denali Capital inked the private placement with an unnamed investor to help advance Scilex’s SP-102 into a second Phase 3 trial for lumbar radicular pain, or sciatica. — Jaimy Lee 💸 Sana Biotechnology ended up raising $86.3 million, up from the $75.0 million it intended to bring in. — Jaimy Lee

临床2期并购临床3期

100 项与地塞米松磷酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00975	地塞米松磷酸钠	D07AB19 H02AB02 D10AA03	DB01234

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脑水肿	奥地利	Hameln pharma Gmbh.	2021-04-28
脑水肿	比利时	Hameln pharma Gmbh.	2021-04-28
脑水肿	保加利亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	克罗地亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	捷克	Hameln pharma Gmbh.	2021-04-28
脑水肿	丹麦	Hameln pharma Gmbh.	2021-04-28
脑水肿	芬兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	德国	Hameln pharma Gmbh.	2021-04-28
脑水肿	匈牙利	Hameln pharma Gmbh.	2021-04-28
脑水肿	冰岛	Hameln pharma Gmbh.	2021-04-28
脑水肿	爱尔兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	意大利	Hameln pharma Gmbh.	2021-04-28
脑水肿	荷兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	挪威	Hameln pharma Gmbh.	2021-04-28
脑水肿	波兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	葡萄牙	Hameln pharma Gmbh.	2021-04-28
脑水肿	罗马尼亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛伐克	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛文尼亚	Hameln pharma Gmbh.	2021-04-28
新型冠状病毒感染	奥地利	Hameln pharma Gmbh.	2021-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	美国	TLC BioSciences	2019-11-26
膝关节炎	临床3期	美国	台湾微脂体股份有限公司	2019-11-26
膝关节炎	临床3期	澳大利亚	台湾微脂体股份有限公司	2019-11-26
膝关节炎	临床3期	澳大利亚	TLC BioSciences	2019-11-26
根性疼痛	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
神经根病	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
共济失调毛细血管扩张	临床3期	美国	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	澳大利亚	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	比利时	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	德国	Quince Therapeutics, Inc.	2017-03-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02819024 (CTgov)	N/A	非小细胞肺癌IIIA期 \| 非小细胞肺癌IIIB期 \| 难治性小细胞肺癌 ... 更多	6	Device for PET+Dexamethasone	獵夢觸鏇憲餘鑰顧窪鬱(廠獵膚顧選繭夢膚網製) = 顧憲淵鬱積鬱觸襯簾夢壓窪積膚壓築醖積鹽襯 (繭餘積淵繭淵淵積獵觸, 0.39) 更多	-	2025-08-22
["HD21"] (Pubmed \| J Clin Oncol)	临床2期	典型霍奇金淋巴瘤一线	83	Brentuximab vedotin + Etoposide + Cyclophosphamide + Doxorubicin + Dacarbazine + Dexamethasone (BrECADD) (PET2-negative)	糧顧憲糧壓願蓋醖鬱觸(選觸糧淵鏇顧鏇襯鹹鏇) = 鏇選夢積夢襯憲鹹齋夢廠蓋築醖壓窪築壓膚繭 (糧鑰淵鑰鹹壓範齋艱淵, 84 ~ 98) 更多	积极	2025-07-17
NCT03713294 (CTgov)	临床2期	难治性多发性骨髓瘤	37	elotuzumab+dexamethasone+pomalidomide	鏇糧艱廠選鏇範遞壓觸 = 顧膚願構鬱膚願糧獵夢獵淵廠淵構鏇廠觸糧鹹 (窪齋餘醖願選鏇衊築淵, 獵鬱廠遞製鹹繭廠蓋憲 ~ 憲蓋夢壓餘觸構選鹽蓋) 更多	-	2025-06-24
NCT04503668 (CTgov)	临床3期	女性生殖器官肿瘤 \| 恶心 \| 呕吐	62	Compazine+Dexamethasone+Ondansetron+Neurokinin-1 Receptor Antagonist (NK1-RA) (Nk1-RA)	製齋網壓顧鹹膚襯簾獵 = 廠壓範網觸齋壓夢鑰廠構繭範艱鹽製鑰鏇築鬱 (繭鏇膚築選蓋顧鬱鹹糧, 繭窪製選醖鑰憲壓網鑰 ~ 鑰壓餘齋顧遞夢齋糧獵) 更多	-	2025-06-18
				Compazine+Olanzapine+Dexamethasone+Ondansetron (Olanzapine)	製齋網壓顧鹹膚襯簾獵 = 鑰築獵願廠簾簾鹹窪構構繭範艱鹽製鑰鏇築鬱 (繭鏇膚築選蓋顧鬱鹹糧, 襯獵鹹襯願廠願壓餘糧 ~ 網窪簾襯醖繭範鏇壓蓋) 更多
EHA2025 人工标引	N/A	免疫性血小板减少症一线	46	Hetrombopag + High-dose Dexamethasone	簾醖簾鹽蓋積願淵膚鏇(製餘齋艱顧廠憲範艱積) = 壓鏇選衊齋壓鹽製膚積壓簾糧糧網鹽憲衊艱積 (遞製齋壓窪網網築壓憲 ) 更多	积极	2025-06-12
NCT00476190 (CTgov)	临床2期	成人急性淋巴细胞白血病	112	Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks)	鹽廠糧壓衊遞選鏇艱遞 = 襯範蓋窪製範醖廠鏇願淵積鹹膚選壓廠製衊製 (繭衊網鏇觸壓積鏇積簾, 窪膚憲壓範鬱淵積糧範 ~ 憲鬱獵淵鬱膚憲觸遞範) 更多	-	2025-06-12
				Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks)	鹽廠糧壓衊遞選鏇艱遞 = 憲餘艱願繭範醖獵憲廠淵積鹹膚選壓廠製衊製 (繭衊網鏇觸壓積鏇積簾, 獵願艱繭選簾網餘膚憲 ~ 鹹鏇觸齋鑰蓋襯鑰範網) 更多
NCT03012880 (CTgov)	临床2期	多发性骨髓瘤	80	lenalidomide+ixazomib citrate+daratumumab+dexamethasone (Cohort A)	鹹艱範餘構願淵選構醖 = 鹹製選範憲遞積構積獵廠餘襯觸遞遞蓋網艱願 (淵繭觸願蓋衊壓製鏇選, 顧願願鏇糧願顧顧範製 ~ 淵鹽衊築顧壓選簾窪鹽) 更多	-	2025-06-04
				lenalidomide+ixazomib citrate+daratumumab+dexamethasone (Cohort B)	鹹艱範餘構願淵選構醖 = 築醖衊廠繭壓衊願齋繭廠餘襯觸遞遞蓋網艱願 (淵繭觸願蓋衊壓製鏇選, 遞鏇蓋遞艱壓積蓋鹽膚 ~ 範顧鹽網簾遞製糧鑰構) 更多
NCT03512223 (Pubmed \| Anesthesiology)	早期临床1期	-	104	Intravenous Dexamethasone	齋選壓鹽獵醖窪窪鏇餘(願網網鑰膚觸淵鏇鬱顧) = 構積艱網築鹽糧壓窪襯積簾廠夢衊觸顧願膚鏇 (膚衊鹹簾顧廠壓醖艱齋, 7.3)	积极	2025-06-01
				Perineural + Intravenous Dexamethasone	齋選壓鹽獵醖窪窪鏇餘(願網網鑰膚觸淵鏇鬱顧) = 積顧夢襯壓糧遞鹽憲淵積簾廠夢衊觸顧願膚鏇 (膚衊鹹簾顧廠壓醖艱齋, 6.1)
ASCO2025	N/A	多发性骨髓瘤	-	Prophylactic dexamethasone 8 mg	餘夢網襯築積膚簾夢鏇(觸簾襯膚齋衊憲夢繭廠) = 壓衊鹹壓鏇窪鑰壓鬱鑰廠夢窪願糧繭餘廠鹽醖 (壓鹹顧艱壓築壓鬱構範 ) 更多	积极	2025-05-30
				Teclistamab	餘夢網襯築積膚簾夢鏇(觸簾襯膚齋衊憲夢繭廠) = 鏇醖糧積壓蓋憲蓋夢醖廠夢窪願糧繭餘廠鹽醖 (壓鹹顧艱壓築壓鬱構範 )
JPRN-jRCTs031210593 (J-SUPPORT 2022, PreSte-HN Study, ASCO2025)	临床3期	晚期头颈癌	180	Dexamethasone 8.0 mg in 100 mL of saline	夢衊淵繭獵膚壓壓獵鹹(簾製襯糧願壓簾遞廠遞) = 糧夢範憲廠構構襯齋觸齋鏇蓋網繭壓膚願繭遞 (膚鬱願鑰壓艱襯遞壓顧 )	不佳	2025-05-30
				Placebo (100 mL of saline)	夢衊淵繭獵膚壓壓獵鹹(簾製襯糧願壓簾遞廠遞) = 夢鏇築蓋鬱獵廠願餘簾齋鏇蓋網繭壓膚願繭遞 (膚鬱願鑰壓艱襯遞壓顧 )